Tricyclo Ring System Having The Additional Six-membered Nitrogen Hetero Ring As One Of The Cyclos Patents (Class 514/253.03)
-
Publication number: 20040142937Abstract: The present invention provides the use of heterocyclic amine-type compounds to prevent or reduce neuronal damages in patients afflicted with or susceptible to disease states or conditions known to result in or cause neuronal damage.Type: ApplicationFiled: October 21, 2003Publication date: July 22, 2004Inventors: Haiyan Wu, Jo Ann Oostveen, Vimala Hiralal Sethy, Edward Dallas Hall, Robert Bradford McCall
-
Publication number: 20040138226Abstract: In its many embodiments, the present invention provides a novel class of compounds as inhibitors of type 3 17&bgr;-hydroxysteroid dehydrogenase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with type 3 17&bgr;-hydroxysteroid dehydrogenase using such compounds or pharmaceutical compositions.Type: ApplicationFiled: December 15, 2003Publication date: July 15, 2004Applicant: SCHERING CORPORATIONInventors: Timothy J. Guzi, Yi-Tsung Liu, Ronald J. Doll, Anil Saksena, Viyyoor M. Girijavallabhan, Jonathan A. Pachter
-
Publication number: 20040116407Abstract: The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient two compounds simultaneously or within 14 days of each other in amounts sufficient to treat the patient.Type: ApplicationFiled: July 11, 2003Publication date: June 17, 2004Inventors: Alexis Borisy, Curtis Keith, Michael A. Foley, Brent R. Stockwell, Debra A. Gaw, M. James Nichols, Margaret S. Lee
-
Patent number: 6743794Abstract: The present invention further relates to a method of inhibiting MRP1 in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I).Type: GrantFiled: May 21, 2002Date of Patent: June 1, 2004Assignee: Eli Lilly and CompanyInventors: Rosanne Bonjouklian, Jeffrey Daniel Cohen, Joseph Michael Gruber, Douglas Webb Johnson, Louis Nickolaus Jungheim, Julian Stanley Kroin, Peter Ambrose Lander, Ho-Shen Lin, Mark Christopher Lohman, Brian Stephen Muehl, Bryan Hurst Norman, Vinod Francis Patel, Michael Enrico Richett, Kenneth Jeff Thrasher, Sreenivasarao Vepachedu, Wesley Todd White, Yongping Xie, Jeremy Schulenburg York, Brandon Lee Parkhurst, Qiupang Wang
-
Patent number: 6740661Abstract: Disclosed are compounds of the formula: wherein R13 represents an imidazole ring; R14 represents a carbamate, urea, amide or sulfonamide group; R8 represents H when the alkyl chain between the amide group and the R13 imidazole group is substituted, or R8 represents a substituent such as arylalkyl, heteroarylalkyl or cycloalkyl; and the remaining substituents are as defined herein. Also disclosed are compounds wherein R8 is H, and the alkyl chain between the amide group and the R13 imidazole group is unsubstituted. Also disclosed is a method of treating cancer and a method of inhibiting farnesyl protein transferase using the disclosed compounds.Type: GrantFiled: December 20, 2001Date of Patent: May 25, 2004Assignee: Schering CorporationInventors: Arthur G. Taveras, Ronald J. Doll, Alan B. Cooper, Johan A. Ferreira, Timothy Guzi, Alan K. Mallams, Dinanath F. Rane, Viyyoor M. Girijavallabhan, Adriano Afonso, Cynthia J. Aki, Jianping Chao, Carmen Alvarez, Joseph M. Kelly, Tarik Lalwani, Jagdish A. Desai, James J-S Wang, Jay Weinstein
-
Publication number: 20040087592Abstract: Disclosed is a method of treating Malaria comprising administering an effective amount of an FPT inhibitor to a patient in need of such treatment alone or in combination with an additional antimalarial agent and/or agent for reversing antimalarial resistance.Type: ApplicationFiled: October 21, 2003Publication date: May 6, 2004Inventors: William T. Windsor, Patricia C. Weber, James J-S. Wang, Corey O. Strickland, F. George Njoroge, Timothy J. Guzi, Viyyoor M. Girijavallabhan, Johan A. Ferreira, Jagdish A. Desai, Alan B. Cooper, Michael Gelb
-
Publication number: 20040082578Abstract: This invention provides novel arylindenopyridines of the formula: 1Type: ApplicationFiled: September 27, 2002Publication date: April 29, 2004Inventors: Geoffrey R. Heintzelman, Kristin M. Averill, John H. Dodd, Keith T. Demarest, Yuting Tang, Paul F. Jackson
-
Publication number: 20040082588Abstract: The present invention provides methods for using tricyclic amide compounds, such as 1Type: ApplicationFiled: September 29, 2003Publication date: April 29, 2004Applicant: Schering CorporationInventors: Ellen W. Evans, Wai Nang Choy, Elmer J. Mirro
-
Patent number: 6723733Abstract: This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.Type: GrantFiled: May 15, 2001Date of Patent: April 20, 2004Assignee: Guilford Pharmaceuticals, Inc.Inventors: Jia-He Li, Vincent J. Kalish, Jie Zhang, Larisa E. Serdyuk, Dana Victor Ferraris, Ge Xiao, Paul W. Kletzly
-
Patent number: 6720332Abstract: Oxindole derivatives, specifically pyrrolo[3,2-f]quinoline-2-ones, which are useful as CDK4 inhibitors are described herein. The described invention also includes methods of making such oxindole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.Type: GrantFiled: February 27, 2003Date of Patent: April 13, 2004Assignee: SmithKline Beecham CorporationInventors: Scott Howard Dickerson, David Harold Drewry, James Andrew Linn
-
Publication number: 20040048875Abstract: The present invention provides 1,4 substituted piperazines, 1,4 substituted piperidines, and 1-substituted,4-alkylidenyl piperidines compounds. The compounds of the invention are dual acting molecules having both leukotriene inhibition properties as well as antihistaminergic properties. The compounds of the invention are useful for treating conditions in which there is likely to be a histamine and/or leukotriene component. These conditions include preferably asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, chronic obstructive pulmonary disease, thrombotic disease and otitis media. Also provided are methods of treating asthma and rhinitis by administering an effective asthma and rhinitis-relieving amount of the compounds to a subject in need thereof.Type: ApplicationFiled: August 8, 2003Publication date: March 11, 2004Applicant: UCB S.A.Inventors: Ralph Scannell, Pierre Chatelain, Anna Toy-Palmer, Edmond Differding, James Ellis, Marie-Agnes Lassoie, Michelle Young, Xiong Cai, Sajjat Hussoin, Gurmit Grewal, Timothy Lewis
-
Patent number: 6699864Abstract: The present invention provides compounds of the formula: wherein R1-R8, X, Y, Z, n and m are defined in the application. The compounds of the invention have affinity for the 5-HT1A receptor.Type: GrantFiled: June 20, 2002Date of Patent: March 2, 2004Assignee: H. Lundbeck A/SInventors: Thomas Ruhland, Christian Krog-Jensen, Mario Rottländer, Gitte Mikkelsen, Ejner Knud Moltzen, Kim Andersen
-
Patent number: 6699872Abstract: Novel halo-N-substituted urea compounds and pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel halo-N-substituted urea compound to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammals such as a human.Type: GrantFiled: November 1, 2001Date of Patent: March 2, 2004Assignee: Schering CorporationInventors: Stacy W. Remiszewski, Alan K. Mallams
-
Publication number: 20040038970Abstract: The present invention is directed to compounds of formula (I) wherein the variables are defined in the specification, which bind to somatostatin receptors and block Na channels.Type: ApplicationFiled: March 7, 2003Publication date: February 26, 2004Applicant: Societe de Conseils de Recherches etd' Application Scientifiques, S.A.S. a Paris, France corp.Inventors: Christophe Alain Thurieau, Lydie Francine Poitout, Marie-Odile Galcera, Christophe Philippe Moinet, Thomas D. Gordon, Barry A. Morgan, Dennis C. H. Bigg, Jacques Pommier
-
Patent number: 6693198Abstract: Disclosed is a salt of amonafide or amonafide analogs represented Structural Formula (I): R1 is —(CH2)nN+HR3R4 X− or R1 is —(CH2)nN+HR3R4 X− or —(CH2)nNR3R4 when R2 is —N+HR6R7. R2 is —OR5, halogen, —NR6R7, —N+HR6R7 X− sulphonic acid, nitro, —NR5COOR5, —NR5COR5 or —OCOR5; R3 and R4 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitrogen-containing heterocyclic group; each R5 is independently —H or a C1-C4 alkyl group; R6 and R7 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitrogen-containing heterocyclic group; n is an integer from 0-3; and X− is the carboxylate anion of an organic carboxylic acid compound. Also disclosed are methods of preparing certain compounds represented by Structural Formula (I).Type: GrantFiled: April 22, 2002Date of Patent: February 17, 2004Assignee: Xanthus Life Sciences, Inc.Inventors: Alfred M. Ajami, David O. Barlow
-
Patent number: 6693112Abstract: The present invention provides 2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-4-ylamines, of the formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R7 are as defined herein. Also disclosed are pharmaceutical compositions comprising such compounds, and methods for using the compounds to increase the therapeutic efficacy of drugs.Type: GrantFiled: June 19, 2002Date of Patent: February 17, 2004Assignee: The Pennsylvania State UniversityInventor: Charles D. Smith
-
Publication number: 20040029877Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain sulfonamide or sulfonamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: ApplicationFiled: December 21, 2001Publication date: February 12, 2004Inventors: Stephen L. Crooks, Kyle J. Lindstrom, Bryon A. Merrill, Michael J. Rice
-
Publication number: 20040023955Abstract: The present invention relates to tricyclic 2-pyridone compounds of formula (I): 1Type: ApplicationFiled: June 10, 2003Publication date: February 5, 2004Inventors: James D. Rodgers, Haisheng Wang, Mona Patel, Argyrios Arvanitis, Anthony J. Cocuzza
-
Patent number: 6677349Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain sulfonamide or sulfonamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: GrantFiled: April 28, 2003Date of Patent: January 13, 2004Assignee: 3M Innovative Properties CompanyInventor: George W. Griesgraber
-
Publication number: 20040006079Abstract: The invention relates to novel 2,4-dihydro-pyrrolo[3,4-b]quinolin-9-one derivatives of the formula (I) and (IV): 1Type: ApplicationFiled: June 17, 2003Publication date: January 8, 2004Inventors: Weiqin Jiang, Zhihua Sui
-
Publication number: 20030232818Abstract: Antibacterials having formula (I) 1Type: ApplicationFiled: March 12, 2003Publication date: December 18, 2003Inventors: David Anderson, Bruce Beutel, Todd D. Bosse, Richard Clark, Curt Cooper, Peter Dandliker, Caroline David, Yu-Gui Gu, Todd Matthew Hansen, Mira Hinman, Douglas Kalvin, Daniel P. Larson, Linda Lynch, Zhenkun Ma, Christopher Motter, Fabio Palazzo, Teresa Rosenberg, Tamara Rehm, William Sanders, Michael Tufano, Rolf Wagner, Moshe Weitzberg, Hong Yong, Tianyuan Zhang
-
Publication number: 20030229099Abstract: Disclosed are novel tricyclic compounds represented by the formula (1.Type: ApplicationFiled: February 27, 2002Publication date: December 11, 2003Inventors: Hugh Y. Zhu, F. George Njoroge, Alan B. Cooper, Timothy Guzi, Dinanath F. Rane, Keith P. Minor, Ronald J. Doll, Viyyoor M. Girijavallabhan, Bama Santhanam, Patrick A. Pinto, Bancha Vibulbhan, Kartik M. Keertikar, Carmen S. Alvarez, John J. Baldwin, Ge Li, Chia-Yu Huang, Ray A. James, W. Robert Bishop, James J-S Wang, Jagdish A. Desai
-
Publication number: 20030225036Abstract: The present invention provides novel compounds of the Formula (I) its prodrug forms, or pharmaceutically acceptable salts thereof. Preferred (I) compounds of the present invention comprise a pyrrolo pyridinyl, pyrrolo pyrimidinyl or indole nucleus. The compounds of this invention are inhibitors of Factor Xa (FXa), Factor VIIa (FVIIa) and/or serine proteases, Urokinase (uPA), and have utility as anti-coagulants for the treatment or prevention of thromboembolic disorders in mammals and as anticancer agents.Type: ApplicationFiled: March 24, 2003Publication date: December 4, 2003Inventors: Aleksandr Kolesnikov, Roopa Rai
-
Publication number: 20030220347Abstract: The present invention provides 1,4 substituted piperazines, 1,4 substituted piperidines, and 1-substituted,4-alkylidenyl piperidines compounds. The compounds of the invention are dual acting molecules having both leukotriene inhibition properties as well as antihistaminergic properties. The compounds of the invention are useful for treating conditions in which there is likely to be a histamine and/or leukotriene component. These conditions include preferably asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, chronic obstructive pulmonary disease, thrombotic disease and otitis media. Also provided are methods of treating asthma and rhinitis by administering an effective asthma and rhinitis-relieving amount of the compounds to a subject in need thereof.Type: ApplicationFiled: September 12, 2002Publication date: November 27, 2003Applicant: UCB S.A.Inventors: Ralph Scannell, Pierre Chatelain, Anna Toy-Palmer, Edmond Differding, James Ellis, Marie-Agnes Lassoie, Michelle Young, Xiong Cai, Sajjat Hussoin, Gurmit Grewal, Timothy Lewis
-
Publication number: 20030216373Abstract: Compounds of the formula (I), or a pharmaceutically acceptable salt, or an in-vivo-hydrolysable ester thereof, 1Type: ApplicationFiled: May 6, 2003Publication date: November 20, 2003Inventors: Michael Barry Gravestock, Michael John Betts, Ian Richard Matthews, David Alan Griffin
-
Publication number: 20030212061Abstract: The present invention relates to a group of aza-thioxanthenone compounds having antitumor activity, and processes for their preparation. Compositions containing the aza-thioxanthenone compounds and methods of treating tumors and cancer in mammals with the compounds of the present invention are also disclosed.Type: ApplicationFiled: March 12, 2002Publication date: November 13, 2003Inventor: Simon N. Haydar
-
Patent number: 6645966Abstract: Disclosed is a method of treating Malaria comprising administering an effective amount of an FPT inhibitor to a patient in need of such treatment alone or in combination with an additional antimalarial agent and/or agent for reversing antimalarial resistance. Also disclosed are novel Farnesyl Protein Transferase inhibitors.Type: GrantFiled: January 18, 2002Date of Patent: November 11, 2003Assignee: Schering CorporationInventors: William T. Windsor, Patricia C. Weber, Corey O. Strickland, Michael Gelb
-
Publication number: 20030203893Abstract: The invention relates to benzimidazole derivatives of general formula 1Type: ApplicationFiled: January 30, 2003Publication date: October 30, 2003Inventors: Francis Barth, Daniel Bichon, Frank Bolkenius, Viviane Van Dorsselaer
-
Patent number: 6638929Abstract: This invention provides compounds of formula 1, having the structure which are useful as inhibitors of protein tyrosine kinase and are antiproliferative agents.Type: GrantFiled: December 29, 2000Date of Patent: October 28, 2003Assignee: WyethInventors: Dan M. Berger, Minu D. Dutia, Frenel F. DeMorin, Diane H. Boschelli, Dennis W. Powell, Hwei-Ru Tsou, Allan Wissner, Nan Zhang, Fei Ye, Biqi Wu
-
Patent number: 6638935Abstract: The invention relates to novel pyridine derivatives of formula 1, to their preparation and to their use as medicaments, in particular for treating tumorsType: GrantFiled: July 20, 2001Date of Patent: October 28, 2003Assignee: Zentaris AGInventors: Peter Emig, Eckhard Günther, Bernhard Kutscher, Bernd Nickel, Jürgen Schmidt, Anita Storch
-
Patent number: 6635638Abstract: The invention relates to novel pyrrolopyridinone derivatives of the formula (I) or (II): pharmaceutical compositions containing the compounds and their use for the treatment of sexual dysfunction.Type: GrantFiled: May 2, 2001Date of Patent: October 21, 2003Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Zhihua Sui, Mark J. Macielag, Jihua Guan, Weiqin Jiang, James C. Lanter
-
Publication number: 20030195186Abstract: Many males and females experience sexual dysfunction either caused or made worse by medications, other substances, diseases, and other medical conditions. Currently, there is need for additional treatment alternatives for these patients' sexual dysfunction. The subject invention provides a novel treatment for these individuals with sexual dysfunction by inhibiting the enzyme that breaks down acetylcholine (a compound that helps modulate normal sexual function) and elevates acetylcholine levels in the body.Type: ApplicationFiled: April 10, 2003Publication date: October 16, 2003Applicant: University of FloridaInventor: Nathan Andrew Shapira
-
Publication number: 20030195189Abstract: Oxindole derivatives, specifically pyrrolo[3,2-f]quinoline-2-ones, which are useful as CDK4 inhibitors are described herein. The described invention also includes methods of making such oxindole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.Type: ApplicationFiled: February 27, 2003Publication date: October 16, 2003Inventors: Scott Howard Dickerson, David Harold Drewry, James A. Linn
-
Publication number: 20030166637Abstract: The present invention relates to substituted piperazine derivatives of general formula 1Type: ApplicationFiled: October 9, 2002Publication date: September 4, 2003Inventors: Thorsten Lehmann-Lintz, Armin Heckel, Leo Thomas, Michael Mark
-
Publication number: 20030162791Abstract: The invention relates to novel phenylpiperazine derivatives of the formula wherein: —R represents the group (a) or (b) as indicated in the description. These compounds are (partial) D2 receptor agonists and are usefull for treating CNS disorders, in particular Parkinson's disease.Type: ApplicationFiled: January 30, 2003Publication date: August 28, 2003Inventors: Roelof W Feenstra, Eric Ronken, Cornelis G Kruse, Andrew C McCreary, Gustaaf J.M. van Scharrenburg
-
Patent number: 6608078Abstract: The present invention relates to optically pure 8-(substituted piperidino)-benzo[i,j]quinolizines, their isomers, derivatives, salts, pseudopolymorphs, polymorphs prodrugs and hydrates thereof, to processes for their preparation, and to pharmaceutical compositions comprising 8-(substituted piperidino)-benzo[i,j]quinolizines their isomers, derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof. These compounds and compositions possess potent activity in treating local and systemic infections, particularly infections caused by sensitive and resistant Gram-positive organism infections, Gram-negative organism infections, mycobacterial infections and nosocomial pathogens, and particularly those belonging to the staphylococcus, streptococcus and enterococcus groups. Methods for treating the diseases and disorders arising from the foregoing infections in humans and animals are described by administering the compounds of the invention to said humans and animals.Type: GrantFiled: May 7, 2001Date of Patent: August 19, 2003Assignee: Wockhardt LimitedInventors: Noel John De Souza, Mahesh Vithalbhai Patel, Shiv Kumar Agarwal, Shirkant V Gupte, Dilip J Upadhyay, Satish B Bhawsar, Mohammad A Jafri
-
Publication number: 20030153561Abstract: The present invention provides a compound of formula I 1Type: ApplicationFiled: November 5, 2002Publication date: August 14, 2003Inventors: Valerie A. Vaillancourt, Sandra Staley, Audris Huang, Richard Allen Nugent, Ke Chen, Sajiv K. Nair, James A. Nieman, Joseph Walter Strohbach
-
Patent number: 6605610Abstract: Compounds of the formula and their pharmaceutically acceptable salts, wherein R1, R2, and R3 are as defined herein; intermediates for the synthesis of such compounds, pharmaceutical compositions containing such compounds; and methods of using such compounds in the treatment of neurological and psychological disorders.Type: GrantFiled: February 25, 2000Date of Patent: August 12, 2003Assignee: Pfizer IncInventors: Jotham Wadsworth Coe, Paige Roanne Palmer Brooks
-
Publication number: 20030144283Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.Type: ApplicationFiled: December 21, 2001Publication date: July 31, 2003Inventors: Patrick L. Coleman, Stephen L. Crooks, George W. Griesgraber, Kyle J. Lindstrom, Bryon A. Merrill, Michael J. Rice
-
Publication number: 20030144267Abstract: The invention provides compounds of general formula (I) wherein Q, R, R2, R4, R5, R6, R7 and R8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.Type: ApplicationFiled: October 18, 2002Publication date: July 31, 2003Inventors: Peter Hansen, Lars Pettersson
-
Publication number: 20030134846Abstract: Disclosed is a method of treating and or preventing infections of Trypanosoma brucei by administering to a patient, in need of such treatment, an effective amount of a Farnesyl Protein Transferase Inhibitor alone or in combination with an additional anti-Trypanosoma brucei agent and/or an anti-Trypanosoma brucei resistance reversing agent.Type: ApplicationFiled: October 7, 2002Publication date: July 17, 2003Applicant: Schering CorporationInventors: William T. Windsor, Patricia C. Weber, Corey Strickland, Rosalinda Syto, Viyyoor M. Girijavallabhan, James J. Kaminski, Zhuyan Guo
-
Publication number: 20030134844Abstract: This invention relates to the use of nicotinic acetylcholine receptor agonists for the treatment of restless legs syndrome (RLS). The invention further relates to the use of a nicotinic acetylcholine receptor agonist in the manufacture of a medicament for the treatment of RLS. The present invention also relates to a pharmaceutical composition for the treatment of RLS containing a nicotinic acetylcholine receptor agonist.Type: ApplicationFiled: August 20, 2002Publication date: July 17, 2003Applicant: Pfizer Inc.Inventor: Mario D. Saltarelli
-
Publication number: 20030130277Abstract: This invention provides a compound of the formula (I): 1Type: ApplicationFiled: July 9, 2002Publication date: July 10, 2003Inventors: Kiyoshi Kawamura, Sachiko Mihara, Seiji Nukui, Chikara Uchida
-
Publication number: 20030114442Abstract: The present invention relates to substituted piperazine derivatives of general formula 1Type: ApplicationFiled: October 8, 2002Publication date: June 19, 2003Inventors: Armin Heckel, Thorsten Lehmann-Lintz, Leo Thomas, Michael Mark
-
Patent number: 6566362Abstract: Benzo[f]naphthyridine derivatives of formula (I): benzo[f]naphthyridine derivatives and benzo[f]naphthyridine esters of formula (IVa): aminoquinoline derivatives of formula (X): processes for preparing such compounds; and compositions comprising them.Type: GrantFiled: December 31, 2001Date of Patent: May 20, 2003Assignee: Aventis Pharma S.A.Inventors: Jean-François Desconclois, Arielle Genevois-Borella, Philippe Girard, Michel Kryvenko, Marc Pierre Lavergne, Jean-Luc Malleron, Guy Picaut, Michel Tabart, Sylvie Wentzler
-
Publication number: 20030092705Abstract: Disclosed is a method of treating Malaria comprising administering an effective amount of an FPT inhibitor to a patient in need of such treatment alone or in combination with an additional antimalarial agent and/or agent for reversing antimalarial resistance.Type: ApplicationFiled: January 18, 2002Publication date: May 15, 2003Applicant: Schering CorporationInventors: William T. Windsor, Patricia C. Weber, James J-S Wang, Corey O. Strickland, F. George Njoroge, Timothy J. Guzi, Viyyoor M. Girijavallabhan, Johan A. Ferreira, Jagdish A. Desai, Alan B. Cooper, Michael Gelb
-
Patent number: 6559186Abstract: Sympathetically maintained pain is treated topically by administering to the site where sympathetically maintained pain is present an &agr;-1-adrenergic antagonist, &agr;-2-adrenergic agonist, or other drug that depletes or blocks synthesis of sympathetic norepinephrine, known collectively as sympatholytic agents. Chemical formulas for several sympatholytic agents are given.Type: GrantFiled: August 5, 1994Date of Patent: May 6, 2003Assignee: Arc 1, Inc.Inventor: James N. Campbell
-
Patent number: 6548506Abstract: Novel 1,8-benzo-naphthyridine derivatives of general formula (I): which are useful as antimicrobial agents.Type: GrantFiled: June 20, 2001Date of Patent: April 15, 2003Assignee: Aventis Pharma S.A.Inventors: Jean-François Desconclois, Guy Picaut, Philippe Girard, Michel Tabart, Sylvie Wentzler
-
Publication number: 20030064034Abstract: The present invention relates to an inhaled formulation comprising a compound selected from a particular class of 5,6-dihydro-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridines which is capable of delivering the compound as fine, solid particles to the lung and the use of such a formulation in the treatment of certain diseases such as respiratory diseases. By the use of such formulations, it is possible to eliminate the unwanted cough response associated with the use of these compounds in solution metered dose inhalers, which response can prevent the administration of a therapeutically effective dose and, in the long term, undermine patient compliance.Type: ApplicationFiled: September 5, 2002Publication date: April 3, 2003Inventors: Michael John Humphrey, Paul Robert Miller, Michael Trevor Shepherd
-
Patent number: 6541483Abstract: The present invention relates to several novel acridone-derived compounds of of formula (I) or (II). These compounds are potent anti-viral agents, useful in the treatment of viral diseases, such as Human Immunodeficiency Virus. In addition, these compounds are anti-neoplastic agents useful in the treatment of various forms of cancer. wherein R1 and R2 are independently —H, —OH, amino, alkylamino, dialkylamino, alkoxy, alkyl, haloalkyl or halogen; n is 2 to 6, X and X′ are independently —N or —NO2; Y and Y′ are independently —N or —CH, or —H; and the double-slash represents a double bond or no bond.Type: GrantFiled: January 15, 2001Date of Patent: April 1, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Christopher J. Michejda, Marek W. Cholody, William G. Rice, James A. Turpin